Concert posts 3Q profit Thu, 09 Nov 2017 15:50:48 +0000 On a per-share basis, the Lexington, Massachusetts-based company said it had net income of $5.44. Losses, adjusted for non-recurring gains, came to 70 cents per share. The biopharmaceutical company posted ...
Concert Pharmaceuticals, Inc. to Host Earnings Call Thu, 09 Nov 2017 13:23:00 +0000 NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 8:30 AM ...
Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)? Mon, 06 Nov 2017 13:52:10 +0000 Concert Pharmaceuticals Inc (NASDAQ:CNCE), a biotechnology company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. With many analystsRead More...
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial Mon, 06 Nov 2017 12:00:00 +0000 Concert Pharmaceuticals, Inc. today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543. Concert is developing CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.
Concert Pharmaceuticals, Inc. – Value Analysis (NASDAQ:CNCE) : October 17, 2017 Tue, 17 Oct 2017 14:10:34 +0000 Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Concert Pharmaceuticals, Inc. a score of 14. Our analysis is based on comparing Concert Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Jazz Pharmaceuticals Plc, Ardelyx, Inc., AbbVie, Inc., GW Pharmaceuticals PLC Sponsored ADR, Ionis Pharmaceuticals, Inc. and Trevena, Inc. (CELG-US, JAZZ-US, ARDX-US, ABBV-US, GWPH-US, IONS-US ... Read more
(Read more...)
Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017 Mon, 16 Oct 2017 12:33:01 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Concert Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more
(Read more...)
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.